Health Advance Inc.

Health Advance Inc., a development stage company, operates as an on-line retailer of home medical products in Canada and the United States. It intends to offers aids to daily living, ambulatory, bath safety, core wound care, diabetic, enteral nutrition-feeding, home diagnostics, incontinence, orthopedic, ostomy, pain management, professional use and diagnostic, respiratory, tracheostomy care, specialty wound care, and women-infant products. The company's product portfolio would also include bed accessories, catheters, diagnostic equipment, lift chairs/geri chairs, IV supplies, needles/syringes, patient lifts and acc, personal protection products/gloves, scooters and accessories, seating/cushions, specialty medical equipment and accessories, urological/collection devices, wheelchairs accessories. It focuses on operating leadingmedicalproducts.com, an e-commerce site for the retail community and health care community. The company intends to serve health care professionals, medical distributors, and consumers. Health Advance Inc. was founded in 2010 and is based in Las Vegas, Nevada.

Health Advance Inc. trades as HADV on OTC. The company is classified in Healthcare / Medical - Pharmaceuticals and reports in USD.

The current profile places the business in Medical - Pharmaceuticals. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $0 of revenue and -$49,022 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Health Advance Inc. can be compared against peers such as Abattis Bioceuticals Corp., AXM Pharma, Inc., Psykey, Inc., Decision Diagnostics Corp., Immunotech Laboratories, Inc., Isodiol International Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $32,189, beta of -0.23, and return on equity of +116.8%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

HADV currently shows total debt of $272,028 and beta of -0.23. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: SC 13G/A (2025-02-07 00:00:00), SC 13G/A (2024-07-05 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.healthadvanceinc.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.